IRCT2013020612380N1 IRCT 2013-05-07 Aryogen biopharma co. Comparing the cost-effectiveness of two alternative bypassing agents (aryoseven & feiba )for haemophilia Comparing the cost-effectiveness of two alternative bypassing agents (aryoseven & feiba) for patients with hemophilia A complicated by an inhibitor in Iran 2013-02-19 anticipated 30 Complete https://irct.ir/trial/12439 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. 3 Haemophilia. Intervention 1: Intervention group1: patients based on the belief treatment & based on previous history (questionnaire available) are divided into consumer Aryo (Group A), two bleeding event in each category will be discussed.(which is a very important factor in the effectiveness of treatment and could be confounding factors in most studies, it is not accurate) and medication requirements, and form of CRF (monitoring symptoms during 1,3,6,9,12 ) will be delivered. Protocol A • Injection Dosage: The dose of 90-120 mg / kg body weight (mean 100 mg / kg body weight) • Injection time - 0 hours and 3 - 6 pm If pain assessment and limitations Moving clocks 3 and 6 are both negative dose of 270 mg / kg injection - at 9 or 12 for the assessment of pain and limitations of movement is negative, just one more dose of 270 mg / kg injections (up to 2 times per stroke, bleeding dosage 3 to be given). Intervention 2: Intervention group 2: Patient care based on the belief & treatment history (according to the questionnaire) will be divided into consumer Faiba (Group F): 2 bleeding event in each category will be discussed 1,3,6,9,12 ) will be delivered. Protocol F (Appendix Figure 2): • First dose at zero time :50-75 units / kg body weight • Second dose at 9 pm only if both pain and limitation of movement in 6 and 9pm are negative (no improvement in 6 hours Recent or severe pain 9) with 75 to 100 units / kg will repeat. • * If both protocols is less than 8 out of the 12 hours following drug treatment will change, but the calculation model, the drug has no further role. Intervention 3: Control group: because of consistency of study the patients are divided into control group(O) Indifferent or new.